Literature DB >> 16916663

Sequence analysis of major histocompatibility complex class-II DQB1 (Patr-DQB1) alleles in chimpanzees by polymerase chain reaction-based methods.

EunJung Bak1, Yoshiyuki Ishii, Tsutomu Omatsu, Shigeru Kyuwa, Tetsuya Tanoue, Ikuo Hayasaka, Yasuhiro Yoshikawa.   

Abstract

The major histocompatibility complex (MHC) class-II genes are described as the genes that encode the antigen-presenting molecule. In particular, functional alleles of MHC class-II genes in nonhuman primates have been analyzed as part of the study of infectious and immune-mediated diseases in animal models and as part of efforts to understand the molecular evolution of human leukocyte antigen. The polymorphisms and sequence analysis of MHC class-II genes in a large number of subjects is necessary for the group management of nonhuman primates. In the present study, we attempted to analyze the DQB1 polymorphism in the common chimpanzee (Pan troglodytes) by exon 2 sequencing. For exact typing of Patr-DQB1 alleles, we carried out polymerase chain reaction-restriction fragment length polymorphism and sequence analysis. In the genomic DNA of 25 chimpanzees, 6 Patr-DQB1 alleles, including 2 new alleles, were detected. Identification and analysis of Patr-DQB1 alleles using this method may contribute to our understanding of Patr-DQB1 allelic diversity in individual chimpanzees and should be useful in facilitating colony management of chimpanzee groups in Japan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916663     DOI: 10.1016/j.humimm.2006.04.016

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  1 in total

1.  Similar patterns of genetic diversity and linkage disequilibrium in Western chimpanzees (Pan troglodytes verus) and humans indicate highly conserved mechanisms of MHC molecular evolution.

Authors:  Christelle Vangenot; José Manuel Nunes; Gaby M Doxiadis; Estella S Poloni; Ronald E Bontrop; Natasja G de Groot; Alicia Sanchez-Mazas
Journal:  BMC Evol Biol       Date:  2020-09-15       Impact factor: 3.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.